Long-Term Effectiveness and Drug Survival of Secukinumab in Vietnamese Patients with Psoriasis: Results from a Retrospective ENHANCE Study

Nguyen, Hieu; Pham, Nhi Thi Uyen; Tran, Tu Nguyen Anh; Pham, Nguyen Nhat; Bui, Yen Thi; Vu, Thao Thi Phuong

doi:10.1007/s13555-022-00867-y

Cited by 9 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ixekizumab DS in our study appears to be higher than the one for of secukinumab and anti‐TNFalpha at 5 years, and similar to brodalumab at 2 years, reported in some real‐life studies 4,18–20 …”

Section: Discussionsupporting

confidence: 84%

See 1 more Smart Citation

Drug survival, effectiveness and safety of ixekizumab for moderate‐to‐severe psoriasis up to 5 years

Mastorino,

Dapavo,

Burzi

et al. 2023

Acad Dermatol Venereol

View full text Add to dashboard Cite

IntroductionIxekizumab proved to be effective and safe for psoriasis treatment in several randomized clinical trials and real‐life studies. Nevertheless, long‐term real‐world experiences are still lacking, with little data up to 4 years of treatment.ObjectivesTo analyse survival, effectiveness and safety of ixekizumab in a real‐life cohort of patients affected by moderate‐to‐severe psoriasis or psoriatic arthritis up to 260 weeks (5 years).MethodsWe included all patients treated with ixekizumab from December 2017 to March 2021. Drug survival (DS) was analysed in patients at risk for up to 5 years. Cox analysis was adopted to evaluate possible predictive factors of discontinuation. Psoriasis Area Severity Index (meanPASI and PASI100, 90, and ≤3) was used as outcomes of effectiveness on observed patients at 16, 52, 104, 156, 208 and 260 weeks. Logistic regression was performed to identify possible predictive factors of response.ResultsDS was 65.5% at 260 weeks, with being a super‐responder patient (achievement of PASI100 at 16 weeks and maintained at 28 weeks) correlated with less risk of discontinuation. PASI100, 90 and ≤3 was achieved by 54.1%, 60.5% and 73% of observed patients, respectively, at 16 weeks, and by 59.1%, 81.8% and 95.5%, respectively, at 260 weeks. High mean BMI was the only factor strongly associated with less achievement of the outcomes at the earlier time points: PASI100 at 16 weeks (OR 0.93, CI 0.87–0.98, p = 0.014) and at 104 weeks (OR 0.91, CI 0.84–0.98, p = 0.019), PASI90 achievement at 16 weeks (OR 0.94, CI 0.88–0.99, p = 0.028) and 104 weeks (OR 0.91, CI 0.83–0.99, p = 0.027), and PASI ≤3 (OR 0.86, CI 0.76–0.97, p = 0.018) at 104 weeks. No severe adverse events were observed.ConclusionsIxekizumab showed high effectiveness and safety for up to 5 years, with survival of 2/3 of treated patients. Rapid response to treatment is predictive of long‐term response.

show abstract

Section: Discussionsupporting

confidence: 84%

“…4,17 Ixekizumab DS in our study appears to be higher than the one for of secukinumab and anti-TNFalpha at 5 years, and similar to brodalumab at 2 years, reported in some real-life studies. 4,[18][19][20] The limitation of the present study is inherent to the retrospective monocentric design and only observed case analysis.…”

Section: Discussionmentioning

confidence: 96%

Drug survival, effectiveness and safety of ixekizumab for moderate‐to‐severe psoriasis up to 5 years

Mastorino,

Dapavo,

Burzi

et al. 2023

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Summary drug survival curves in blue, separate studies in grey. A Secukinumab [ 24 – 26 , 33 , 34 , 39 – 41 , 44 , 46 , 48 , 50 , 51 , 53 , 62 , 64 , 68 , 70 , 72 , 74 , 80 – 85 ], B ixekizumab [ 23 , 32 , 33 , 39 , 40 , 42 – 44 , 46 , 49 , 62 , 70 , 81 , 84 , 85 ], C brodalumab [ 39 , 40 , 58 , 62 , 84 – 87 ], D guselkumab [ 29 , 30 , 33 , 35 , 37 , 43 , 44 , 50 , 59 , 70 , 84 , 85 , 88 , 89 ], E risankizumab [ 27 , 50 , 84 , 85 , 90 ], ...…”

Section: Resultsmentioning

confidence: 99%

Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis

Thomas,

Barenbrug,

Hannink

et al. 2024

Drugs

View full text Add to dashboard Cite

Background and Objective The most recently approved biologics for moderate-to-severe psoriasis are the interleukin (IL)-17 and IL-23 inhibitors. Drug survival is a frequently used outcome to assess drug performance in practice. An overview of the available drug survival studies regarding IL-17 and IL-23 inhibitors is lacking. Therefore, our objective was to assess the drug survival of IL-17 and IL-23 inhibitors for psoriasis. Methods A search of PubMed, Embase, Cochrane Library and Web of Science was conducted (last search 27 December, 2023). Inclusion criteria were (1) cohort study; (2) patients aged ≥ 18 years with plaque psoriasis; and (3) evaluation of drug survival of at least one of the IL-17 and IL-23 inhibitors. Exclusion criteria were: primary focus on patients with psoriatic arthritis, fewer than ten study subjects and another language than English. The Preferred Reporting Items for Systematic Reviews and Meta-analyses reporting guideline was followed. Survival probabilities at monthly intervals were extracted from Kaplan–Meier curves using a semi-automated tool. Data were pooled using a non-parametric random-effects model to retrieve distribution-free summary survival curves. Summary drug survival curves were constructed per biologic for different discontinuation reasons: overall, ineffectiveness and adverse events, and split for the effect modifier biologic naivety. Results were analysed separately for registry/electronic health record data and for pharmacy/claims data. Results A total of 69 studies aggregating drug survival outcomes of 48,704 patients on secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, and tildrakizumab were included. Summary drug survival estimates of registry/electronic health record studies for overall, ineffectiveness and adverse event related drug survival were high (all point estimates ≥ 0.8 at year 1) for included biologics, with highest estimates for guselkumab and risankizumab. All estimates for drug survival were higher in biologic naive than in experienced patients. Estimates of pharmacy/claims databases were substantially lower than estimates from the primary analyses based on registry/electronic health record data. Conclusions This meta-analysis showed that the investigated IL-17 and IL-23 inhibitors had high drug survival rates, with highest rates for guselkumab and risankizumab drug survival. We showed that effect modifiers such as biologic naivety, and the source of data used (registry/electronic health record data vs pharmacy/claims databases) is relevant when interpreting drug survival studies. Supplementary Information The online version contains supplementary material available at 10.1007/s40265-024-02028-1.

show abstract

Real-Life Data of Secukinumab in Patients with Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis: Patient Baseline Characteristics Data from the PROMPT Study

Rattanakaemakorn,

Chevaisrakul,

Wongpraparut

et al. 2024

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Long-Term Effectiveness and Drug Survival of Secukinumab in Vietnamese Patients with Psoriasis: Results from a Retrospective ENHANCE Study

Cited by 9 publications

References 26 publications

Drug survival, effectiveness and safety of ixekizumab for moderate‐to‐severe psoriasis up to 5 years

Drug survival, effectiveness and safety of ixekizumab for moderate‐to‐severe psoriasis up to 5 years

Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis

Real-Life Data of Secukinumab in Patients with Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis: Patient Baseline Characteristics Data from the PROMPT Study

Contact Info

Product

Resources

About